Genovis Q3 2023: Solid growth and profitability, Xork timeline remains on track - Redeye

Redeye updates its view on Genovis following its Q3 2023 report and the announced merger between Selecta and Cartesian Therapeutics. We continue to see an exciting and compelling growth case, which should offer an attractive opportunity in the share in 2024.

Länk till analysen i sin helhet: https://www.redeye.se/research/960102/genovis-q3-2023-strong-development-in-analytics-and-timeline-for-xork-project-remains-intact?utm_source=finwire&utm_medium=RSS